Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ion Channel Protein TRPM7 Required for Breast Tumor Cell Metastasis in a Mouse Xenograft Model

By LabMedica International staff writers
Posted on 23 Aug 2012
A recent study identified the ion channel protein TRPM7 (transient receptor potential cation channel, subfamily M, member 7) as being required for breast tumor cell metastasis.

TRPM7 is both an ion channel and a serine/threonine protein kinase. More...
The kinase activity is essential for the ion channel function, which serves to increase intracellular calcium levels and to help regulate magnesium ion homeostasis. TRPM7 had been implicated in control of cell adhesion and migration, but whether TRPM7 activity contributes to cancer progression had not been established.

In a recent study, investigators at Radbound University Medical Center (Nijmegen, the Netherlands) evaluated whether the level of expression of the TRPM7 gene correlated with breast cancer progression.

They reported in the August 7, 2012, online edition of the journal Cancer Research that in primary breast tumors removed at diagnosis from a cohort of 368 women, high levels of expression from the TRPM7 gene were associated with significantly shorter times to both recurrence of disease and occurrence of distant metastases. This association was validated in an independent cohort of 144 breast cancer patients.

Experiments conducted with a mouse xenograft model of human breast cancer revealed that TRPM7 was functionally required for metastasis formation. Mechanistic investigation revealed that TRPM7 regulated myosin II–based cellular tension, thereby modifying focal adhesion number, cell–cell adhesion, and polarized cell movement.

“The most important discovery that we report in this paper is that TRPM7 is required for metastasis, at least in a xenograft model of breast cancer metastasis,” said contributing author Dr. Frank van Leeuwen, assistant professor of pediatric oncology at Radbound University Medical Center. “While this fundamental biological finding will not have an immediate impact on patient care, we believe that it opens the door to a previously under-explored area of cancer therapeutics.

“TRPM7 functions as a cation channel,” said Dr. van Leeuwen. “As such, it is in a class of proteins that is already therapeutically targeted to treat diseases; for example, cation channel blockers are used to treat several heart conditions. Given that cation channels are druggable; our data provide clear rationale for probing whether drugs that target this class of proteins could block metastasis.”

Related Links:
Radbound University Medical Center




New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.